Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000085.xml
Download PDF
Thorac Cardiovasc Surg 2022; 70(08): 677-683
DOI: 10.1055/s-0041-1728714
DOI: 10.1055/s-0041-1728714
Review Article
Old Borders and New Horizons in Multimodality Imaging of Malignant Pleural Mesothelioma
Abstract
Background The purpose of this article is to describe the various imaging techniques involved in detection, staging, and preoperative planning in malignant pleural mesothelioma (MPM) focusing on new imaging modalities.
Methods For this purpose, first a brief summary of the etiology of MPM is given. Second, not only the commonly known, but also novel imaging modalities used in MPM will be discussed.
Results A wide range of imaging methods, from conventional chest radiography, through computed tomography and hybrid imaging to radiomics and artificial intelligence, can be used to evaluate MPM.
Conclusion Nowadays multimodality imaging is considered the cornerstone in MPM diagnosis and staging.
Publication History
Received: 28 January 2021
Accepted: 08 March 2021
Article published online:
01 June 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27 (12) 2081-2090
- 2 Falaschi F, Romei C, Fiorini S. et al. Imaging of malignant pleural mesothelioma: it is possible a screening or early diagnosis program?—a systematic review about the use of screening programs in a population of asbestos exposed workers. J Thorac Dis 2017; 10( (Suppl. 02) S262-S268
- 3 Nickell Jr LT, Lichtenberger III JP, Khorashadi L, Abbott GF, Carter BW. Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma. Radiographics 2014; 34 (06) 1692-1706
- 4 Gill RR, Tsao AS, Kindler HL. et al. Radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol 2019; 14 (10) 1718-1731
- 5 Sinha S, Swift AJ, Kamil MA. et al. The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines. Clin Radiol 2020; 75 (06) 423-432
- 6 Dynes MC, White EM, Fry WA, Ghahremani GG. Imaging manifestations of pleural tumors. Radiographics 1992; 12 (06) 1191-1201
- 7 Craighead JE. Current pathogenetic concepts of diffuse malignant mesothelioma. Hum Pathol 1987; 18 (06) 544-557
- 8 Wang ZJ, Reddy GP, Gotway MB. et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 2004; 24 (01) 105-119
- 9 Bonomo L, Feragalli B, Sacco R, Merlino B, Storto ML. Malignant pleural disease. Eur J Radiol 2000; 34 (02) 98-118
- 10 Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol 2015; 10 (09) 1240-1242
- 11 Miller A, Widman SA, Miller JA, Manowitz A, Markowitz SB. Comparison of x-ray films and low-dose computed tomographic scans: demonstration of asbestos-related changes in 2760 nuclear weapons workers screened for lung cancer. J Occup Environ Med 2013; 55 (07) 741-745
- 12 Ricciardi S, Cardillo G, Zirafa CC. et al. Surgery for malignant pleural mesothelioma: an international guidelines review. J Thorac Dis 2018; 10 (Suppl. 02) S285-S292
- 13 Alexander E, Clark RA, Colley DP, Mitchell SE. CT of malignant pleural mesothelioma. AJR Am J Roentgenol 1981; 137 (02) 287-291
- 14 Miller BH, Rosado-de-Christenson ML, Mason AC, Fleming MV, White CC, Krasna MJ. From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation. Radiographics 1996; 16 (03) 613-644
- 15 Leung AN, Müller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 1990; 154 (03) 487-492
- 16 Corson N, Sensakovic WF, Straus C, Starkey A, Armato III SG. Characterization of mesothelioma and tissues present in contrast-enhanced thoracic CT scans. Med Phys 2011; 38 (02) 942-947
- 17 Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 1999; 172 (04) 1039-1047
- 18 Armato III SG, Blyth KG, Keating JJ. et al. Imaging in pleural mesothelioma: a review of the 13th International Conference of the International Mesothelioma Interest Group. Lung Cancer 2016; 101: 48-58
- 19 Lococo F, Rena O, Torricelli F. et al. 18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results. Interact Cardiovasc Thorac Surg 2020; 30 (04) 593-596
- 20 Marom EM, Erasmus JJ, Pass HI, Patz Jr EF. The role of imaging in malignant pleural mesothelioma. Semin Oncol 2002; 29 (01) 26-35
- 21 Frauenfelder T, Kestenholz P, Hunziker R. et al. Use of computed tomography and positron emission tomography/computed tomography for staging of local extent in patients with malignant pleural mesothelioma. J Comput Assist Tomogr 2015; 39 (02) 160-165
- 22 Patel AM, Berger I, Wileyto EP. et al. The value of delayed phase enhanced imaging in malignant pleural mesothelioma. J Thorac Dis 2017; 9 (08) 2344-2349
- 23 Patel A, Roshkovan L, McNulty S. et al. Delayed-phase enhancement for evaluation of malignant pleural mesothelioma on computed tomography: a prospective cohort study. Clin Lung Cancer 2020; S1525-7304 (20) 30184-4
- 24 Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16 (01) 145-152
- 25 Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113 (03) 723-731
- 26 Murphy DJ, Gill RR. Volumetric assessment in malignant pleural mesothelioma. Ann Transl Med 2017; 5 (11) 241
- 27 Frauenfelder T, Tutic M, Weder W. et al. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?. Eur Respir J 2011; 38 (01) 162-168
- 28 Proto C, Signorelli D, Mallone S. et al. The prognostic role of TNM staging compared with tumor volume and number of pleural sites in malignant pleural mesothelioma. Clin Lung Cancer 2019; 20 (06) e652-e660
- 29 Plathow C, Klopp M, Thieke C. et al. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur Radiol 2008; 18 (08) 1635-1643
- 30 Chen M, Helm E, Joshi N, Gleeson F, Brady M. Computer-aided volumetric assessment of malignant pleural mesothelioma on CT using a random walk-based method. Int J CARS 2017; 12 (04) 529-538
- 31 Appenzeller P, Mader C, Huellner MW. et al. PET/CT versus body coil PET/MRI: how low can you go?. Insights Imaging 2013; 4 (04) 481-490
- 32 Antoch G, Vogt FM, Freudenberg LS. et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003; 290 (24) 3199-3206
- 33 Huellner MW, Appenzeller P, Kuhn FP. et al. Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: preliminary observations. Radiology 2014; 273 (03) 859-869
- 34 Martini K, Meier A, Opitz I. et al. Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma. Lung Cancer 2016; 94: 40-45
- 35 Yildirim H, Metintas M, Entok E. et al. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol 2009; 4 (12) 1480-1484
- 36 Lim JH, Choi JY, Im Y. et al. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma. PLoS One 2020; 15 (02) e0229299
- 37 Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 2010; 67 (03) 311-317
- 38 Zucali PA, Lopci E, Ceresoli GL. et al. Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. Cancer Med 2017; 6 (10) 2287-2296
- 39 Choudhury A. Predicting cancer using supervised machine learning: Mesothelioma. Technol Health Care 2021; 29 (01) 45-58
- 40 Weyn B, Van De Wouwer G, Koprowski M. et al. Value of morphometry, texture analysis, densitometry, and histometry in the differential diagnosis and prognosis of malignant mesothelioma. J Pathol 1999; 189 (04) 581-589
- 41 Pena E, Ojiaku M, Inacio JR. et al. Can CT and MR shape and textural features differentiate benign versus malignant pleural lesions?. Acad Radiol 2017; 24 (10) 1277-1287
- 42 Pavic M, Bogowicz M, Kraft J. et al. FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients. EJNMMI Res 2020; 10 (01) 81
- 43 Rusch VW. From the International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995; 108 (04) 1122-1128
- 44 Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res 2018; 7 (05) 543-549
- 45 Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15 (02) 257-260
- 46 Scherpereel A, Opitz I, Berghmans T. et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 2020; 55 (06) 1900953
- 47 Falaschi F, Boraschi P, Musante F. et al. The computed tomographic diagnosis of malignant pleural mesothelioma. A multicenter study [in Italian]. Radiol Med (Torino) 1992; 84 (1–2): 43-47
- 48 Ollier M, Chamoux A, Naughton G, Pereira B, Dutheil F. Chest CT scan screening for lung cancer in asbestos occupational exposure: a systematic review and meta-analysis. Chest 2014; 145 (06) 1339-1346
- 49 Prezzi D, Khan A, Goh V. Perfusion CT imaging of treatment response in oncology. Eur J Radiol 2015; 84 (12) 2380-2385
- 50 Sudarski S, Shi J, Schmid-Bindert G. et al. Dynamic volume perfusion computed tomography parameters versus RECIST for the prediction of outcome in lung cancer patients treated with conventional chemotherapy. J Thorac Oncol 2015; 10 (01) 164-171
- 51 Gudmundsson E, Labby Z, Straus CM. et al. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. Eur Radiol 2019; 29 (02) 682-688
- 52 Lennartz S, Le Blanc M, Zopfs D. et al. Dual-energy CT-derived iodine maps: use in assessing pleural carcinomatosis. Radiology 2019; 290 (03) 796-804
- 53
Willemink MJ,
Persson M,
Pourmorteza A,
Pelc NJ,
Fleischmann D.
Photon-counting CT: technical principles and clinical prospects. Radiology 2018; 289
(02) 293-312
MissingFormLabel